Neuro-oncology advances最新文献

{"title":"ONC206 as a low-potency dopamine D₂ receptor antagonist.","authors":"Richard Ågren, Kristoffer Sahlholm","doi":"10.1093/noajnl/vdaf185","DOIUrl":"10.1093/noajnl/vdaf185","url":null,"abstract":"","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"7 1","pages":"vdaf185"},"PeriodicalIF":4.1,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12449126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145115744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of progression-free and overall survival following temozolomide chemoradiation using FET PET-based parameters including radiomics in patients with glioblastoma.","authors":"Isabelle Stetter, Jan-Michael Werner, Michael Wollring, Garry Ceccon, Keith George Ciantar, Gabriele Stoffels, Felix M Mottaghy, Gereon R Fink, Karl-Josef Langen, Philipp Lohmann, Norbert Galldiks","doi":"10.1093/noajnl/vdaf196","DOIUrl":"10.1093/noajnl/vdaf196","url":null,"abstract":"<p><strong>Background: </strong>Early after surgery and completion of first-line radiotherapy with concomitant temozolomide, the prediction of progression-free and overall survival (PFS, OS) is of considerable interest for managing patients with glioblastoma.</p><p><strong>Methods: </strong>Sixty-three newly diagnosed patients with glioblastoma (age range, 19-82 years) who received PET imaging using the radiolabeled amino acid <i>O</i>-(2-[¹⁸F]fluoroethyl)-L-tyrosine (FET) after surgery or biopsy and completion of radiotherapy with concomitant temozolomide were evaluated. Static FET PET parameters, that is, maximum and mean tumor-to-brain ratios (TBR_max, TBR_mean), metabolic tumor volumes (MTV), and the dynamic FET PET parameters time-to-peak (TTP) and slope were obtained. Additionally, <i>n</i> = 1,303 FET PET radiomics features were extracted per patient, of which 15 robust features were selected for further evaluation based on test-retest analysis. The prognostic values of FET PET parameters and radiomics features were evaluated using receiver-operating-characteristic (ROC) analyses regarding a favorable PFS and OS. Subsequently, univariate and multivariate survival estimates were performed to assess the prognostic value of these parameters in predicting a significantly longer PFS and OS.</p><p><strong>Results: </strong>ROC analyses revealed that static parameters (ie, TBR_max, MTV) and one radiomics feature were the most powerful parameters to predict a significantly longer PFS (all <i>P</i> = .002) and OS (all <i>P</i> ≤ .02). In addition, the dynamic parameter TTP predicted a significantly longer OS (<i>P</i> ≤ .03) but not PFS (<i>P</i> > .05). TBR_max, MTV, and one radiomics feature remained significant in multivariate survival analysis (all <i>P</i> ≤ .03).</p><p><strong>Conclusion: </strong>Our results suggest that FET PET parameters, including radiomics, are highly prognostic in patients with glioblastoma at an early stage of first-line therapy.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"7 1","pages":"vdaf196"},"PeriodicalIF":4.1,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12458579/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145152451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of palliative care at the time of stereotactic radiosurgery on healthcare utilization for frail patients with brain metastases.","authors":"Trent Kite, Teigan Dwyer, Charlotte Drury-Gworek, Tyson Barrett, John Herbst, Rachel Ombres, Leah Herbst, Stephen Karlovits, Rodney E Wegner, Matthew J Shepard","doi":"10.1093/noajnl/vdaf186","DOIUrl":"10.1093/noajnl/vdaf186","url":null,"abstract":"<p><strong>Background: </strong>The 5-factor modified frailty index (mFI-5) has been increasingly studied in the context of patients with central nervous system tumors. Previously, studies have demonstrated an inverse relationship between increasing mFI-5 scores and overall/progression-free survival in patients with brain metastases (BMs) undergoing stereotactic radiosurgery (SRS).</p><p><strong>Methods: </strong>A single payer insurance database was queried for patients undergoing SRS for BMs. Patients were stratified based on mFI-5 scores as follows: pre-frail (0-1), frail (2), and severely frail (≥ 3). Survival trends and healthcare utilization rates following treatment were analyzed across each frailty group.</p><p><strong>Results: </strong>A total of 9927 patients were retrospectively analyzed. Overall survival (OS) was significantly decreased in the frail and severely frail groups compared to pre-frail patients (frail: HR: 1.55, 95% CI: 1.33-1.80, <i>P</i> < .0001) and (severely frail: HR: 2.12, 95% CI: 1.84-2.44, <i>P</i> < .0001). Increased healthcare utilization was observed after SRS in frail and severely frail patients (frail: 90-day RR 1.07, 180-day RR 1.08. and 1-year RR 1.10, <i>P</i> < .0001; severely frail: 90-day RR 1.16, 180-day RR 1.18, 1-year RR 1.21, <i>P</i> < .0001). In patients with established palliative care involvement at the time of SRS, healthcare utilization rates were decreased in the frail and severely frail groups.</p><p><strong>Conclusion: </strong>Increasing frailty scores portended reduced OS with increased overall healthcare utilization rates. The introduction of palliative care prior to SRS decreased healthcare utilization rates across frailty cohorts.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"7 1","pages":"vdaf186"},"PeriodicalIF":4.1,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12449133/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145115801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Self-assembling polypeptide-drug conjugates as innovative therapeutic candidates for glioblastoma treatment by enhancing intracranial residence time.","authors":"Yunjeong Gwon, Jung Eun Kim, Wooram Jung, Soobin Kim, Kyuri Shin, Yejin Lee, Yoori Choi, Gi Jeong Cheon, Won Bae Jeon","doi":"10.1093/noajnl/vdaf187","DOIUrl":"10.1093/noajnl/vdaf187","url":null,"abstract":"<p><strong>Background: </strong>Glioblastoma (GBM) is the most lethal and incurable brain tumor, with limited treatment options. Systemic delivery of many promising drugs has proven inefficacious due to insufficient brain penetrance. Convection-enhanced delivery (CED) enables direct intracranial infusion of high drug concentrations. However, CED is impaired by rapid drug clearance from the brain, which diminishes its therapeutic benefits.</p><p><strong>Methods: </strong>To develop CED-injectable therapeutics for GBM treatment, two polypeptides, XM147 and XM161, were engineered through tandem recombination of IL4Rα- or IL13Rα2-specific ligands with thermally responsive motifs. XM147-AZDye647 was created by labeling XM147 with the fluorescent dye AZDye647 to study clearance kinetics. Polypeptide-drug conjugates (PDCs), XM147-SN38 and XM161-SN38, were generated by conjugating these polypeptides with the topoisomerase I inhibitor SN38, which is potent but too toxic for use without a drug carrier. The antitumor efficacy of CED-infused XM147-SN38 and XM161-SN38 was evaluated in intracerebral GBM mouse models.</p><p><strong>Results: </strong>XM147 and XM161 exhibited high selectivity and strong binding avidity for their respective receptors. Pharmacokinetic studies of XM147-AZDye647 in non-tumor-bearing mice demonstrated markedly prolonged brain retention following CED. In GBM xenografts, CED-administered XM147-SN38 and XM161-SN38 effectively suppressed tumor growth and significantly extended median survival.</p><p><strong>Conclusion: </strong>These findings provide evidence supporting the use of CED-infused, long-acting PDCs a promising therapeutic strategy for GBM treatment.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"7 1","pages":"vdaf187"},"PeriodicalIF":4.1,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12449142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145115745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting the tumor microenvironment in pediatric gliomas: Advances and future directions in immunotherapy.","authors":"Cheyenne Ahamed, Lam Nguyen, Cayley S Brock, Ayla Farzamnia, Pierrick Millet, Keisaku Sato, Kevin K Kumar","doi":"10.1093/noajnl/vdaf193","DOIUrl":"10.1093/noajnl/vdaf193","url":null,"abstract":"<p><p>The tumor microenvironment (TME) is a critical determinant of tumor progression and therapeutic response in gliomas. While pediatric gliomas have historically been treated using strategies derived from the management of adult gliomas, emerging evidence reveals that pediatric gliomas possess a unique TME. The pediatric TME is distinct, characterized not only by differences in cellular composition but a lower mutational burden, diminished neoantigen presentation, and heightened immunosuppressive activity. The unique immune landscape, developmental trajectories, and immune escape mechanisms in the pediatric TME create barriers to effective therapy. Recent studies show promising results in novel and advanced therapeutic strategies, highlighting the potential for innovative immunotherapeutic approaches. Advances in methodologies for modeling the TME, including computational approaches and animal-based models, provide new insights into pediatric glioma biology. Utilization of computational models may provide opportunities to predict tumor response to specific therapies and tailor immunotherapy regimes to individuals, allowing for personalized care. Leveraging the unique features of the pediatric TME offers an opportunity to overcome current barriers to immunotherapy and develop more effective, age- and tumor-specific treatment strategies.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"7 1","pages":"vdaf193"},"PeriodicalIF":4.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477475/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145201504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of focused ultrasound-induced mechanical ablation on stemness and dormancy properties of residual/peri-focally localized glioblastoma cells.","authors":"Dana Hellmold, Levi Johanning, Jacqueline Clüver, Jonna Holler, Nils Oliver Schröder, Frieda Bayler, Hajrullah Ahmeti, Carolin Kubelt-Kwamin, Sina Wieker, Ann-Kristin Helmers, Michael Synowitz, Janka Held-Feindt","doi":"10.1093/noajnl/vdaf184","DOIUrl":"10.1093/noajnl/vdaf184","url":null,"abstract":"<p><strong>Background: </strong>Focused ultrasound (FUS) is a new technology that enables the spatially and temporally precise delivery of ultrasound energy to various targets. In addition to its known applications in treating tumors, cavitation-based mechanical focused ultrasound (mFUS) is gaining importance. Due to the novelty of this technique, little is known about the effects of mFUS on peri-focally localized or surviving tumor cells. Glioblastomas (GBMs) are highly malignant intracranial tumors with a pronounced intra- and intertumoral heterogeneity, which, eg leads to their evasion of appropriate treatment regimens.</p><p><strong>Methods: </strong>The impact of mFUS was investigated in patient-derived GBM organoids (GBOs), glioma stem-like cells (GSCs), and differentiated GBM cells in an in vitro 3D hydrogel culture model. Particular attention was paid to investigating the stemness and dormancy properties of residual/peri-focally localized GBM cells, as these may be important for tumor progression.</p><p><strong>Results: </strong>In GBOs and different primary cells, increased expression of dormancy- and stemness-associated markers was found in a complex region- and marker-dependent manner mediated via PI3-kinase/Akt/GSK3β signaling, suggesting an effect of mFUS beyond the focal area. mFUS resulted in an increased ability of residual/peri-focal, formerly differentiated patient-derived GBM cells to form stem cell-typical spheres associated with increased expression of various dormancy and stemness markers. Residual/peri-focal patient-derived cells were characterized by a higher resistance to temozolomide, resulting in fewer dead cells compared to temozolomide treatment alone.</p><p><strong>Conclusion: </strong>The ablation of defined regions by mFUS appears to regulate the stemness and dormancy properties of the residual/peri-focally localized GBM cells in a region-specific manner.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"7 1","pages":"vdaf184"},"PeriodicalIF":4.1,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12449158/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145115776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glutamate to GABA ratio is elevated in patients with IDH-mutant lower-grade gliomas and seizures.","authors":"Riccardo Pascuzzo, Roberta Rudà, Peter B Barker, Jianwei Xiang, Luigi Antelmi, Ruben Gianeri, Alessia Pellerino, Francesca Mo, Riccardo Soffietti, Alberto Bizzi","doi":"10.1093/noajnl/vdaf155","DOIUrl":"10.1093/noajnl/vdaf155","url":null,"abstract":"<p><strong>Background: </strong>Patients with IDH-mutant gliomas often experience seizures that significantly affect their quality of life and outcome. Seizure activity may be the result of dysregulation of excitatory (glutamate, Glu) and inhibitory (gamma-aminobutyric acid, GABA) neurotransmitters in peritumoral tissue. A non-invasive measurement of Glu (in combination with glutamine, termed Glx) and GABA is feasible with proton magnetic resonance spectroscopy (¹H-MRS). The aim of this study was to determine whether IDH-mutant glioma patients with seizures exhibit altered Glx and GABA levels compared to patients without seizures.</p><p><strong>Methods: </strong>We conducted a prospective study involving 23 glioma patients (15 with, 8 without seizures), who underwent single-voxel ¹H-MRS using the MEGA-PRESS sequence. ¹H-MRS data were collected from volumes of tissues in the tumor/peritumoral regions and parietal cortex used as control. Metabolite ratios (Glx/Cr, GABA/Cr, Glx/GABA) were analyzed and correlated with seizure presence and other clinical-pathological parameters. Longitudinal ¹H-MRS data in a subset of 10 patients were also acquired.</p><p><strong>Results: </strong>At first study, the Glx/GABA ratio was significantly higher in the tumor/peritumoral tissue of patients with seizures compared to those without (<i>P</i> = .023). Longitudinal data confirmed this finding, showing consistently elevated Glx/GABA values in patients with seizures. Moreover, patients taking two or more antiseizure medications had significantly higher Glx/GABA ratios and lower GABA/Cr ratios in the peritumoral region.</p><p><strong>Conclusion: </strong>Glioma patients with seizures have an altered balance of Glx and GABA in tumor/peritumoral tissue, supporting the hypothesis that neurotransmitter imbalances contribute to seizure activity. ¹H-MRS may provide non-invasive biomarkers for identifying neurotransmitter dysregulation in glioma-related epilepsy.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"7 1","pages":"vdaf155"},"PeriodicalIF":4.1,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12391666/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144984388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is tumor shape associated with molecular diagnosis, extent of resection, or postoperative focal deficits in diffuse low-grade gliomas?","authors":"Claes Johnstad, Ingerid Reinertsen, Alba Corell, Erik Thurin, Tora Dunås, Margret Jensdottir, Jiri Bartek, Klas Holmgren, Rickard L Sjöberg, Francesco Latini, Maria Zetterling, Rupavathana Mahesparan, Peter Milos, Björn Sjögren, Henrietta Nittby Redebrandt, Gregor Tomasevic, Lars Kjelsberg Pedersen, Asgeir S Jakola, Ole Solheim","doi":"10.1093/noajnl/vdaf138","DOIUrl":"10.1093/noajnl/vdaf138","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to explore the potential association between tumor shape, 1p/19q codeletion, EOR, and new postoperative focal deficits in patients with diffuse low-grade glioma.</p><p><strong>Methods: </strong>We analyzed data from 225 WHO grade 2 glioma surgeries performed in nine centers in Norway and Sweden. The tumor measurements were based on automatic segmentations of preoperative T2/FLAIR MRI scans by Raidionics. Contact surface area (CSA) was defined as the area between the tumor and brain parenchyma and was estimated by subtracting the surface area covered by the dura from the total surface area. The sphericity index (SI) was defined as the quotient of the tumor surface area and the surface area of a sphere with equal volume. Focal deficits were defined as any new motor, language, or visual deficits postoperatively.</p><p><strong>Results: </strong>The univariable analyses showed that a larger CSA was associated with higher age (<i>P</i> = .02), lower EOR (<i>P</i> < .0001), and more focal deficits (<i>P</i> = .005) but not with 1p/19q codeletion (<i>P</i> = .54). A higher SI was associated with higher age (<i>P</i> = .02) and lower EOR (<i>P</i> < .0001) but not with focal deficits (<i>P</i> = .08) or 1p/19q codeletion (<i>P</i> = .90). The multivariable linear regression model supported the univariable associations between EOR and CSA (<i>P</i> = .0003) and SI (<i>P</i> = .0013), respectively. Contrarily, the logistic regression model showed that focal deficits were associated with SI (<i>P</i> = .014) but not with CSA (<i>P</i> = .056).</p><p><strong>Conclusion: </strong>The tumor shape appears to be independently associated with EOR and new focal deficits but not with molecular diagnosis in patients with low-grade glioma.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"7 1","pages":"vdaf138"},"PeriodicalIF":4.1,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12448425/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145115754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of the COVID-19 pandemic on primary brain tumor incidence and management: Decisions that went right.","authors":"Melanie Alfonzo Horowitz, Megan Parker, Ryan Gensler, Elizabeth Wang, Alyssa Arbuiso, Karisa C Schreck, Kristin J Redmond, Debraj Mukherjee, Jordina Rincon-Torroella","doi":"10.1093/noajnl/vdaf181","DOIUrl":"10.1093/noajnl/vdaf181","url":null,"abstract":"<p><strong>Background: </strong>The COVID-19 pandemic drastically altered cancer care. Prior reports demonstrated reduced screenings, diagnoses, and disrupted treatment regimens due to multifactorial reasons. We aim to analyze whether the same effects occurred within neuro-oncology.</p><p><strong>Methods: </strong>This analysis included 70 131 patients with primary brain tumors from the SEER database from 2016 to 2021 identified via ICD10 code. The pre-COVID era was 2016-2019, peak-COVID was 2020, and post-COVID was 2021. Multivariate analysis was performed using logistic regression for binary variables and linear regression for continuous. Covariates controlled for were age at diagnosis, sex, and race. NCI SEER*Stat version 8.4.0 was used to calculate incidence rates age-adjusted to the 2000 US standard population and reported per 100 000 persons.</p><p><strong>Results: </strong>Although there was a decrease in the age-adjusted incidence of primary brain tumors between 2016 and 2021, the number of malignant brain tumors remained stable, and this change was likely driven by a reduction in benign tumor incidence. Regarding treatment, in 2020 and 2021 all malignant brain tumors (2020 OR[95%CI]: 1.11[1.02-1.22], 2021: 1.10[1.01-1.020]) and glioblastoma patients (2020 OR[95%CI]: 1.12[1.01-1.26], 2021: 1.13[1.01-1.27]) underwent increased surgical resections, compared to pre-COVID years. Time from diagnosis to treatment decreased for glioblastoma patients in 2020, compared to pre-COVID (Estimate [95%CI]: -1.25 [-1.71 to -0.78]). No treatment changes were noted for benign brain tumors.</p><p><strong>Conclusion: </strong>Malignant tumors, like glioblastoma, maintained a stable incidence due to their aggressive symptoms, though treatment patterns shifted. These findings reveal that the management of malignant brain tumors during the COVID-19 pandemic was effectively prioritized while maintaining quality of care.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"7 1","pages":"vdaf181"},"PeriodicalIF":4.1,"publicationDate":"2025-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12448709/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145115763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A randomized controlled trial of a telehealth group cognitive intervention (LaTCH-BRAINS) to improve cognition after primary brain tumor diagnosis.","authors":"Kerryn E Pike, Sian E B Virtue-Griffiths, Rachel Campbell, Dianne M Legge, Katarzyna Lion, Carl I Moller, Tamara Ownsworth, Mark B Pinkham, Louise Saliba, Ursula M Sansom-Daly, Dean Vuksanovic, Joanne Shaw, Haryana M Dhillon","doi":"10.1093/noajnl/vdaf182","DOIUrl":"10.1093/noajnl/vdaf182","url":null,"abstract":"<p><strong>Background: </strong>Cognitive changes are common following primary brain tumor (PBT), impacting employment, independence, relationships, and quality of life (QoL). Despite this, tailored cognitive interventions are unavailable within Australia. The La Trobe and Caulfield Hospital (LaTCH) group cognitive rehabilitation program has demonstrated efficacy for older adults without PBT. Efficacy for people with PBT was examined using a telehealth adaption of LaTCH.</p><p><strong>Methods: </strong>A Type 1 hybrid-implementation design randomized controlled trial (RCT) with waitlist control (WLC) was used. Adults > 3-months post-PBT diagnosis, and > 1-month post-radiation were randomized to (1) Intervention [6-week group sessions; 2 hours/week], delivered over Zoom (<i>n</i> = 3-7/group) or (2) WLC (intervention offered at 16 weeks). Primary outcomes were self-perceived memory (ability, strategy knowledge and use, satisfaction) and general cognitive function; secondary outcomes included QoL, fatigue, mood, and objective cognition (attention, working memory, processing speed, memory, executive function). Linear mixed models analyzed between-group differences post-intervention and 6 weeks later (maintenance).</p><p><strong>Results: </strong>Sixty participants (<i>M(SD)</i> age = 49.0 (10.4) years, 57% female, 55% high-grade glioma) were randomized (29 intervention, 31 WLC). The intervention group reported significantly improved perceived memory ability, satisfaction, strategy use, and strategy knowledge. Effect sizes were moderate-large (ηp² 0.06-0.21), and maintained for memory ability (<i>t</i> = 4.26, <i>P</i> < .001, ηp² = 0.18), satisfaction (<i>t</i> = 2.23, <i>P</i> = .028, ηp² = 0.18), and strategy knowledge (<i>t</i> = 2.92, <i>P</i> = .004, ηp² = 0.09). Secondary outcomes exhibited no intervention effect.</p><p><strong>Conclusions: </strong>Telehealth-delivered LaTCH-BRAINS improved subjective memory-related outcomes for people with PBT, demonstrating promise as a cognitive rehabilitation approach for people with PBT reporting memory decline.</p><p><strong>Trial registration: </strong>Australian New Zealand Clinical Trials Registry (ACTRN 12622000189729p), registered on 03/02/2022 (Appendix A).</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"7 1","pages":"vdaf182"},"PeriodicalIF":4.1,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12448700/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145115758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}